ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach

Just days after releasing a draft report suggesting that three JAK inhibitors for rheumatoid arthritis would be unlikely to be cost-effective if priced above AbbVie's best-selling Humira, the Institute for Clinical and Economic Review (ICER) has taken the unusual step of backtracking.